Cagrilintide is an investigational weight-loss medication developed by Novo Nordisk. It is a long-acting amylin analogue, designed to be used alongside diet and exercise—and, in some cases, in combination with semaglutide (a GLP-1 receptor agonist)—to help improve weight management in people with overweight or obesity.
How It Works
Cagrilintide mimics the action of amylin, a naturally occurring hormone secreted by the pancreas alongside insulin. Amylin plays an important role in regulating appetite and food intake. Cagrilintide’s main mechanisms include:
-
Slowing gastric emptying – This prolongs the feeling of fullness after meals.
-
Reducing appetite – Signals to the brain help reduce hunger and cravings.
-
Decreasing calorie intake – Over time, this can help create a calorie deficit for weight loss.
Potential Benefits
-
Significant weight loss when used alone or with semaglutide
-
Improved metabolic health markers, such as blood sugar control and lipid profile
-
Once-weekly injection for convenience
-
Dual action when paired with GLP-1 agonists, potentially offering better results than either drug alone
Research & Clinical Data
Early and mid-stage clinical trials have shown promising results:
-
Participants using cagrilintide (with or without semaglutide) experienced substantial weight reductions compared to placebo.
-
Combination therapy appears to outperform semaglutide alone in percentage body weight lost.
Side Effects & Considerations
Commonly reported side effects are similar to those of other gut hormone-based therapies:
-
Nausea
-
Vomiting
-
Constipation
-
Diarrhea
These effects are usually mild to moderate and may improve as the body adapts.
Current Status
Cagrilintide is still in clinical development and has not yet received full regulatory approval in most countries. Ongoing studies are assessing its safety, efficacy, and long-term benefits, especially in combination with semaglutide.
Reviews
There are no reviews yet.